Panel Discussion: Building Sustainable CAR-T Access Through Community Oncology Engagement

• Why community oncology is critical to scaling CAR-T and building infrastructure for long-term patient access
• Key operational and financial differences between academic and community sites that impact market entry
• How reimbursement timelines, coverage policies, and financial risk influence community adoption of high-cost cell therapies

Speakers:

Brad Berigan

Senior Director & Head of Market Access Strategic Account Engagement

Kite Pharma Inc

Michael Byrne

Medical Director, Cellular Therapy

OneOncology

Jillian Fahey

Executive Director, Cell Therapy Patient Access & Field Reimbursement

Bristol Myers Squibb